Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up

Clinical and Vaccine Immunology

Volumn 14, Issue 2, 2007, Pages 129-133

  Boscolo, Marina ^a   Gobbo, Maria ^a   Mantovani, William ^b   Degani, Monica ^a   Anselmi, Mariella ^a   Monteiro, Geraldo Badona ^a   Marocco, Stefania ^a   Angheben, Andrea ^a   Mistretta, Manuela ^a   Santacatterina, Maria ^a   Tais, Stefano ^a   Bisoffi, Zeno ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; TIABENDAZOLE;

ANTIBODY TITER; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FILARIASIS; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STRONGYLOIDIASIS;

AGED; ANIMALS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HUMANS; MALE; STRONGYLOIDES; STRONGYLOIDIASIS;

EID: 33947128134     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00278-06     Document Type: Article

References (63)

1. Adams, M., W. Page, and R. Speare. 14 March 2003, posting date. Strongyloidiasis: an issue in Aboriginal communities. Rural Remote Health 3:152. http://rrh.deakin.edu.au.
2. Adenusi, A. A., A. O. Oke, and A. O. Adenusi. 2003. Comparison of ivermectin and thiabendazole in the treatment of uncomplicated human Strongyloides stercoralis infection. Afr. J. Biotechnol. 2:465-469.
3. Alcaraz, C. O., R. I. Adell, P. S. Sanchez, M. J. Blasco, O. A. Sanchez, A. S. Aunon, and D. R. Calabuig. 2004. Characteristics and geographical profile of strongyloidiasis in healthcare area 11 of the Valencian community (Spain). J. Infect. 49:152-158.
4. Blatt, J. M., and G. A. Cantos. 2003. Evaluation of techniques for the diagnosis of Strongyloides stercoralis in human immunodeficiency virus (HIV) positive and HIV negative individuals in the city of Itajai, Brazil. Braz. J. Infect. Dis. 7:402-408.
5. Bourée, P. 1987. Examens de laboratoire en médecine tropicale, p. 87-88. Masson, Paris, France.
6. Chiodini, P. L., A. J. C. Reid, M. J. Wiselka, R, Firmin, and J. Foweraker. 2000. Parenteral ivermectin in Strongyloides hyperinfection. Lancet 355: 43-44.
7. Concha, R., W. Harrington, Jr., and A. I. Rogers. 2005. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J. Clin. Gastroenterol. 39:203-211.
8. Conway, D. J., A. Hall, K. S. Anwar, M. L. Rahman, and D. A. P. Bundy. 1995. Household aggregation of Strongyloides stercoralis infection in Bangladesh. Trans. R. Soc. Trop. Med. Hyg. 89:258-261.
9. Conway, D. J., N. S. Atkins, J. E. Lillywhite, J. W. Bailey, R. D. Robinson, J. F. Lindo, D. A. P. Bundy, and A. E. Bianco. 1993. Immunodiagnosis of Strongyloides stercoralis infection: a method for increasing the specificity of the indirect ELISA. Trans. R. Soc. Trop. Med. Hyg. 87:173-176.
10. Datry, A., I. Hilmarsdottir, R. Mayorga-Sagastume, M. Lyagoubi, P. Gavotte, S. Giligui, J. Chodakewitz, D. Neu, M. Danis, and M. Gentilizi. 1994. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans. R. Soc. Trop. Med. Hyg. 88:344-345.
11. De Kaminski, R. G. 1993. Evaluation of three methods for laboratory diagnosis of Strongyloides stercoralis infection. J. Parasitol. 79:277-280.
12. Dreyer, G., E. Fernandes-Silva, S. Alves, A. Rocha, R. Albuquerque, and D. Addiss. 1996. Patterns of detection of Strongyloides stercoralis in stool specimens: implications for diagnosis and clinical trials. J. Clin. Microbiol. 34: 2569-2571.
13. Gam, A. A., F. A. Neva, and W. A. Krotoski. 1987. Comparative sensitivity and specificity of ELISA and IHA for serodiagnosis of strongyloidiasis with larval antigens. Am. J. Trop. Med. Hyg. 37:157-161.
14. Gann, P. H., F. A. Neva, and A. A. Gam. 1994. A randomized trial of single-and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J. Infect. Dis. 169:1076-1079.
15. Garcia, L. S., and D. A. Bruckner. 1997. Diagnostic medical parasitology, 3rd ed., p. 656-657. ASM Press, Washington, DC.
16. Genta, R. M. 1992. Dysregulation of strongyloidiasis: a new hypothesis. Clin. Microbiol. Rev. 5:345-355.
17. Genta, R. M. 1987. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am. J. Clin. Pathol. 89:391-394.
18. Genta, R. M., S. Gatti, M. J. Linke, C. Cevini, and M. Scaglia. 1988. Endemic strongyloidiasis in northern Italy: clinical and immunological aspects. Q. J. Med. 68:679-690.
19. Genta, R. M., R. Weesner, R. W. Douce, T. Huitger-O'Connor, and P. D. Walzer. 1987. Strongyloidiasis in US veterans of the Vietnam and other wars. JAMA 258:49-52.
20. Gill, G. V., E. Welch, J. W. Bailey, D. R. Bell, and N. J. Beeching. 2004. Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. O. J. Med. 97:789-795.
21. Grove, D. I. 1996. Human strongyloidiasis. Adv. Parasitol. 38:251-309.
22. Grove, D. I., and A. J. Blair. 1981. Diagnosis of human strongyloidiasis by immunofluorescence, using Strongyloides ratti and S. stercoralis larvae. Am. J. Trop. Med. Hyg. 30:344-349.
23. Gushulak, B. D., and D. W. MacPherson. 2004. Globalization of infectious diseases: the impact of migration. Clin. Infect. Dis. 38:1742-1748.
24. Hakim, S. Z., and R. M. Genta. 1986. Fatal disseminated strongyloidiasis in a Vietnam war veteran. Arch. Pathol. Lab. Med. 110:809-812.
25. Igual-Adell, R., C. Oltra-Alcaraz, E. Soler-Company, P. Sanchez-Sanchez, J. Matogo-Oyana, and D. Rodriguez-Calabuig. 2004. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin. Pharmacother. 12:2615-2619.
26. Johnston, F. H., P. S. Morris, R. Speare, J. McCarthy, B. Currie, D. Ewald, W. Page, and K. Dempsey. 2005. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust. J. Rural Health 13:247-254.
27. Jongwutiwes, S., M. Charoenkorn, P. Sitthichareonchai, P. Akaraborvorn, and C. Putaporntip. 1999. Increased sensitivity of routine laboratory detection of Strongyloides stercoralis and hookworm by agar-plate culture. Trans. R. Soc. Trop. Med. Hyg. 93:398-400.
28. Karunajeewa, H., H. Kelly, D. Leslie, J. Leydon, P. Saykao, and B. A. Biggs. 2006. Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis. J. Travel Med. 13:84-91.
29. Kaslow, J. E., H. S. Novey, R. H. Zuch, and G. S. Spear. 1990. Disseminated strongyloidiasis: an unheralded risk of corticosteroid therapy. J. Allergy Clin. Immunol. 86:138.
30. Keiser, P. B., and T. B. Nutman. 2004. Strongyloides stercoralis in the immunocompromised population. Clin. Microbiol. Rev. 17:208-217.
31. Knottnerus, J. A., C. van Weel, and J. W. Muris. 2002. Evaluation of diagnostic procedures. BMJ 324:477-480.
32. Kobayashi, J., Y. Sato, H. Toma, and Y. Shiroma. 1994. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn. Microbiol. Infect. Dis. 18:19-23.
33. Koosha, S., M. Fesharaki, and M. B. Rokni. 2004. Comparison of enzyme-linked immunosorbent assay and indirect immunofluorescence assay in the diagnosis of human strongyloidiasis. Indian J. Gastroenterol. 23:214-216.
34. Lemos, L. B., Q. Zhenhong, R. Laucirica, and H. L. Fred. 2003. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann. Diagn. Pathol. 7:87-94.
35. Lim, S., K. Katz, S. Krajden, M. Fuksa, J. S. Keystone, and K. C. Kain. 2004. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. Can. J. Med. Assoc. 171:479-484.
36. Lindo, J. F., D. J. Conway, N. S. Atkins, A. E. Bianco, R. D. Robinson, and D. A. P. Bundy. 1994. Prospective evaluation of enzyme-linked immunosorbent assay and immunoblot methods for the diagnosis of endemic Strongyloides stercoralis infection. Am. J. Trop. Med. Hyg. 51:175-179.
37. Lindo, J. F., N. S. Atkins, M. G. Lee, R. D. Robinson, and A. P. Bundy. 1996. Parasite-specific serum IgG following successful treatment of endemic strongyloidiasis using ivermectin. Trans. R. Soc. Trop. Med. Hyg. 90:702-703.
38. Loutfy, M. R., M. Wilson, J. S. Keystone, and K. C. Kain. 2002. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am. J. Trop. Med. Hyg. 66:749-752.
39. Magnaval, J. F., J. M. Mansuy, L. Villeneuve, and S. Cassaing. 1999. A retrospective study of autochthonous strongyloidiasis in Région Midi-Pyrénées (southwestern France). Eur. J. Epidemiol. 16:179-182.
40. Mangali, A., W. Chaicumpa, P. Nontasut, P. Chantavanij, P. Tapchaisri, and C. Viravan. 1991. Enzyme-linked immunosorbent assay for diagnosis of human strongyloidiasis. Southeast Asian J. Trop. Med. Public Health 22: 88-92.
41. . Marti, H., H. J. Haji, L. Savioli, H. M. Chwaya, A. F. Mgeni, J. S. Ameir, and C. Hatz. 1996. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg. 55:477-481.
42. Muennig, P., D. Pallin, R. L. Sell, and M. S. Chan. 1999. The cost-effectiveness of strategies for the treatment of intestinal parasites in immigrants. N. Engl. J. Med. 340:773-779.
43. Nuesch, R., L. Zimmerli, R. Stockli, N. Gyr, and C. Hatz. 2005. Imported strongyloidosis: a longitudinal analysis of 31 cases. J. Travel Med. 12:80-84.
44. Olmos, J. M., S. Gracia, F. Villoria, R. Salesa, and J. Gonzalez-Macias. 2004. Disseminated strongyloidiasis in a patient with acquired immunodeficiency syndrome. Eur. J. Int. Med. 15:529-530.
45. Pacanowski, J., M. Dos Santos, A. Roux, C. Le Maignan, J. Guillot, V. Lavarde, and M. Cornet. 2005. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am. J. Trop. Med. Hyg. 73:122-124.
46. Page, W. A., K. Dempsey, and J. S. McCarthy. 2006. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans. R. Soc. Trop. Med. Hyg. 100:1056-1062.
47. Pirisi, M., E. Salvador, Z. Bisoffi, M. Gobbo, C. Smirne, C. Gigli, R. Minisini, G. Fortina, G. Bellomo, and E. Bartoli. 2006. Unsuspected strongyloidiasis in hospitalized elderly patients with and without cosinophilia. Clin. Microbiol. Infect. 12:787-792.
48. Roman-Sanchez, P., A. Pastor-Guzman, S. Moreno-Guillem, R. Igual-Adell, S. Suner-Generoso, and C. Tornero-Estebanez. 2003. High prevalence of Strongyloides stercoralis among farm workers on the Mediterranean coast of Spain: analysis of the predictive factors of infection in developed countries. Am. J. Trop. Med. Hyg. 69:336-340.
49. Salazar, S. A., C. Gutierrez, and S. L. Berk. 1995. Value of the agar plate method for the diagnosis of intestinal strongyloidiasis. Diagn. Microbiol. Infect. Dis. 23:141-145.
50. Sanchez, P. R., A. P. Guzman, S. M. Guillen, R. I. Adell, A. M. Estruch, I. N. Ponzalo, and C. R. Olmos. 2001. Endemic strongyloidiasis on the Spanish Mediterranean coast. Q. J. Med. 94:357-363.
51. Sato, Y., J. Kobayashi, and Y. Shiroma. 1995. Efficacy of stool examination for detection of Strongyloides infection. Am. J. Trop. Med. Hyg. 53:248-250.
52. Scaglia, M., R. Brustia, S. Gatti, A. M. Bernuzzi, M. Strosselli, A. Malfitano, and D. Capelli. 1984. Autochthonus strongyloidiasis in Italy: an epidemiological and cinical review of 150 cases. Bull. Soc. Pathol. Exot. Filiales 77:328-332.
53. Scaglia, M., S. Gatti, and E. G. Rondanelli. 2006. Strongiloidosi, p. 417-427. In M. Scaglia, S. Gatti, and E. G. Rondanelli (ed.), Parassiti e parassitosi umane. Dalla clinica al laboratorio. Selecta Medica, Pavia, Italy.
54. Schaffel, R., M. Nucci, R. Portugal, M. B. Castro, S. B. Ferriera, L. Almeida, N. Spector, and W. Pulcheri. 2000. Thiahendazole for the treatment of strongyloidiasis in patients with hematologic malignancies. Clin. Infect. Dis. 31:821-822.
55. Siddiqui, A. A., and S. L. Berk. 2001. Diagnosis of Strongyloides stercoralis infection. Clin. Infect. Dis. 33:1040-1047.
56. Sithithaworn, P., T. Srisawangwong, S. Tesana, W. Daenseekaew, J. Sithithaworn, Y. Fujimaki, and K. Ando. 2003. Epidemiology of Strongyloides stercoralis in north-cast Thailand: application of the agar plate culture technique compared with the enzyme-linked immunosorbent assay. Trans. R. Soc. Trop. Med. Hyg. 97:398-402.
57. Speare, R., and D. N. Durrheim. 8 October 2004, posting date. Strongyloides serology - useful for diagnosis and management of strongyloidiasis in rural Indigenous populations, but important gaps in knowledge remain. Rural Remote Health 4:264. http://rrh.deakin.edu.au.
58. Sudarshi, S., R. Stumpfle, M. Armstrong, T. Ellman, S. Parton, P. Krishnan, P. L. Chiodini, and C. J. M. Whitty. 2003. Clinical presentation and diagnostic sensitivity of laboratory tests for Strongyloides stercoralis in travellers compared with immigrants in a non-endemic country. Trop. Med. Int. Health 8:728-732.
59. Uparanukraw, P., S. Phongsri, and N. Morakote. 1999. Fluctuations of larval excretion in Strongyloides stercoralis infection. Am. J. Trop. Med. Hyg. 60: 967-973.
60. Yori, P. P., M. Kosek, R. H. Gilman, J. Cordova, C. Bern, C. B. Chavez, M. P. Olortegui, C. Montalvan, G. M. Sanchez, B. Worthen, J. Worthen, F. Leung, and C. V. Oré. 2006. Seroepidemiology of strongyloidiasis in the Peruvian Amazon. Am. J. Trop. Med. Hyg. 74:97-102.
61. Zaha, O., T. Hirata, F. Kinjo, A. Saito, and H. Fukuhara. 2002. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J. Infect. Chemothcr. 8:94-98.
62. Zaha, O., T. Hirata, N. Uchima, F. Kinjo, and A. Saito. 2004. Comparison of anthelmintic effects of two doses of ivermectine on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J. Infect. Chemother. 10:348-351.
63. Zweig, M. H., and G. Campbell. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39:561-577.